Chemical Synthesis Group

通常情况下，需要帮助的PI或药物开发合作组织（DDC）将项目提交给小组考虑。DDC（由Patricia Steeg和Doug Figg博士担任主席）是一个指导委员会，为CCR研究者提供项目援助，以支持临床前开发。DDC提出的项目通常需要重新合成或简单的药物化学，以使项目在开发中向前推进。在本集团同意开展项目之前，PI将项目正式提交给合成团队，以确定化学、合成可行性、成本、完成时间和替代商业/供应商选项。在PI会议之前，合成团队将已经确定拟定的合成和/或探索供应商选项。在主要参与者会议期间，将决定综合小组是否将开展该项目或建议一种替代办法。特定项目的范围是上下文相关的。有些项目只是“供雇用的综合”，而其他项目则更具协作性质，涉及共同撰写出版物。Joel Schneider积极管理项目。小组会议每周在弗雷德里克举行一次，讨论进展情况，解决化学问题和审查分析数据。在需要时，Jay Schneekloth博士和Martin Schnermann博士会被咨询以制定合成策略。这两个PI在合成方法和天然产物合成方面都有特殊的培训。

Typically, either a PI in need of assistance or the Drug Development Collaborative (DDC) brings projects to the Group for consideration. The DDC (chaired by Drs. Patricia Steeg and Doug Figg) is a steering committee that provides CCR investigators with assistance in their projects to support pre-clinical development. Projects presented by the DDC are typically in need of re-synthesis or simple medicinal chemistry that will allow the project to move forward in development. Before the Group agrees to undertake the project, the PI presents the project formally to the synthesis team to define the chemistry, synthetic feasibility, cost, time-to-completion, and alternate commercial/ vendor options. Prior to the PI meeting, the synthetic team will have already determined a proposed synthesis and/or explored vendor options. During the PI meeting, a decision is made as to whether or not the Synthesis Group will undertake the project or recommend an alternate approach. The scope of a particular project is contextual. Some projects are simply "synthesis for hire" and others are more collaborative in nature and involve co-authoring publications. Joel Schneider actively manages projects. Group meetings are held in Frederick once a week to discuss progress, troubleshoot chemistry and review analytical data. When needed, Drs. Jay Schneekloth and Martin Schnermann are consulted to develop synthetic strategy. Both PIs have exceptional training in synthetic methodology and natural product synthesis.